The diversity of nanobodies binding specifically [in this case to EGF receptor (EGFR)] should allow for efficient targeting of different tumor antigens by enhanced attachment (in this case increased binding of nanobody-targeted vesicles to the EGFR). This evidence concerns the gene EGFR and neoplasm.